Practical Pharmacology for Dementia

DOI Web Site
  • Kudo Takashi
    Department of Psychiatry, Osaka University Health Care Center

Bibliographic Information

Other Title
  • 認知症薬物療法の実際
  • ニンチショウ ヤクブツ リョウホウ ノ ジッサイ

Search this article

Description

So - called Disease - modifying drugs for dementia, especially Alzheimer disease, have been developed vigorously in recent years. However their clinical trials have not been success yet. Therefore, as a drug therapy for Alzheimerʼs disease, symptomatic drugs, that is donepezil, galantamine, rivastigmine, and memantine, must be relied currently. In 2011, WFSBP announced the Guidelines for the Biological Treatment of Alzheimer ʻs disease and other dementias to show the guidelines for the use of symptomatic drugs. Donepezil , the first cholinesterase inhibitor, has a long half- life and a selectivity of the acetylcholine esterase. Galantamine has an allosteric effect on nicotinic receptors as well as a cholinesterase inhibitory activity. Rivastigmine is characterized by having not only an effect on acetylcholine esterase but an effect on. butyrylcholine esterase. Memantine is a glutamate NMDA receptor antagonist to suppress the neuropathy by glutamate. In the light of these features, it is necessary to use symptomatic drugs properly.

Journal

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top